Abstract: The present disclosure relates to using green solvents to synthesize an array of imines, imine-related and imine-derived compounds in an efficient and eco-friendly matter, satisfying green chemistry requirements. Reaction embodiments are performed using solvents, such as ethyl lactate and dimethyl isosorbide, which are both individually characterized as green. In embodiments, solvents include lactic whey and/or water as co-solvents. In these green solvents, the synthesis process discussed herein can produce up to quantitative yields of product at room temperature in a short duration. Embodiments include a method of forming an imine, imine-related or imine-derived compound product. In embodiments, the methods include mixing an aldehyde reactant with a nucleophilic/nitrogen-containing reactant in a green solvent at a temperature between negative twenty degrees Celsius (?20° C.) and positive fifty degrees Celsius (50° C.

Abstract: Described herein are boron-containing compounds, compositions, and methods for their preparation.

Abstract: Provided are novel prodrugs of esuberaprost and pharmaceutical compositions thereof, as well as methods of making and methods of using these prodrugs.

Abstract: This invention is directed to compounds of Formula (I) pharmaceutically acceptable salts, esters, and prodrugs thereof, to their preparation, to pharmaceutical compositions comprising compounds of Formula I, and to their uses as antimicrobial agents.

Abstract: The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.

Abstract: The present invention relates to a method for the production of 5-hydroxymethylfurfural (HMF), which converts a fructose-containing component using a catalyst system comprising a solution of a salt and acid mixture at a temperature of 90 to 200° C. and leads to obtaining an HMF-containing product mixture, wherein advantageously a high HMF selectivity with significantly lower by-product formation is achieved at the same time.

Abstract: The present disclosure is related to the separation of chemical species using multiple liquid phases.

Abstract: This invention discloses cannabinoids linked with polyethylene glycol chains. The cannabinoid-polyethylene glycol chain molecules have one, two, or more cannabinoids linked with one, two, or more polyethylene glycol chains. Each cannabinoid-polyethylene glycol chain molecule may have one kind of cannabinoid or multiple kinds of cannabinoid. Methods to make these cannabinoid-polyethylene glycol linked chains are disclosed.

Abstract: Provided are a peptide borate ester compound or a pharmaceutically acceptable salt thereof, a preparation method therefor, and pharmaceutical use thereof. The peptide borate ester compound or pharmaceutically acceptable salt thereof has a structure as shown in Formula (I), and is useful in the preparation of proteasome inhibitors to treat solid tumors and hematoma.

Abstract: The present invention relates to a laurolactam preparation method and synthesis apparatus, and epoxidation and a rearrangement reaction are performed in the conversion of cyclododecene into cyclododecanone so that the preparation method can synthesize laurolactam having a higher purity with a higher selectivity and in a higher yield than a conventional preparation method.

Abstract: The present disclosure includes compositions and methods for improved DNA amplification reactions. In particular, the present disclosure provides compositions and methods for hot-start PCR applications using DNA polymerase inhibitors that minimize non-specific DNA amplification by inactivating DNA polymerase at lower temperatures.

Abstract: Provided herein are solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Vadadustat, Code: AKB-6548, Compound 1), compositions comprising such solid forms, and methods of making and using thereof.

Abstract: Nitrogen-containing cyclic compounds for color conversion film, and a color conversion film, a backlight unit and a display apparatus including the compound(s).

Abstract: According to the present invention, a lens adhesive including a compound represented by General Formula 1 is provided. Pol1-Sp1-L1-Ar-L2-Sp2-Pol2??(General Formula 1) In the formula, Ar is an aromatic ring group represented by General Formula 2-2 and the like. In the formula, Z1 and Z2 each represent a hydrogen atom, a methyl group, and the like; A1 and A2 each represent —S— and the like; X represents C(Rz)2 and the like (where Rz is a substituent, and two Rz's may form a ring); L1 and L2 each represent a single bond, —O—, —OC(?O)—, —OC(?O)O—, —OC(?O)NH—, and the like; Sp1 and Sp2 each represent a single bond or a linking group such as a linear alkylene group; Pol1 and Pol2 each represent a hydrogen atom or a polymerizable group; and a compound represented by General Formula 1 has at least one polymerizable group. Using the lens adhesive, it is possible to provide a cemented lens that is unlikely to deteriorate due to light, and an imaging module having high durability.

Abstract: The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected from alumina and aluminum alkoxides and in a non-protic solvent wherein at least one carbon atom ortho to the hydroxy group in the hydroxy aryl compound is unsubstituted. The present application also includes compounds of Formula (I).

Abstract: The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to N-(substituted-phenyl)-sulfonamide compounds, which are extremely useful as inhibitors of protein kinases (e.g. PERK kinase) and accordingly can be used for the treatment of cell proliferative disorders, such as cancer, or diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Abstract: Provided herein are compounds, compositions, kits, uses, and methods for assessing the viability of cells and/or quantifying the amount of live and dead cells in a mixture using differential stains. In some embodiments, the compounds are used in culture media or can function independently of fixation and/or permeabilization. In some embodiments, the compounds comprise a platinum atom. In some embodiments, the compounds comprise a nitrogen mustard moiety.

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R5, R6, R7, R8 and the subscript n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of disorders including prostate cancer are also provided.